Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Anti-dumping duty...

    Anti-dumping duty likely on Amoxycillin import from China

    Written by supriya kashyap kashyap Published On 2017-04-11T11:48:32+05:30  |  Updated On 11 April 2017 11:48 AM IST
    Anti-dumping duty likely on Amoxycillin import from China

    New Delhi : India may impose anti-dumping duty of up to USD 8.71 per kg on Amoxycillin, an anti-biotic medicine, from China to ringfence domestic players from cheap imports.


    Aurobindo Pharma had filed the application before the Directorate General of Anti-dumping and Allied Duties (DGAD) for initiation of probe into the import.


    In its findings, the DGAD has concluded that Amoxycillin is entering Indian market from China at "dumped prices".


    Due to this dumping, performance of the domestic industry has deteriorated and "the injury suffered by the domestic industry is significant and material", the DGAD has said in a notification.


    The authority has recommended imposition of anti-dumping duty to remove the effect of the dumped import, it added. The suggested duty ranged between USD 2.83 and USD 8.71 per kg.


    While the DGAD recommends the duty, the finance ministry imposes it.


    Import of Amoxycillin from China increased to 1,255 tonnes during October 2014 and September 2015, from 506 tonnes in 2012-13. It is used to reduce development of drug-resistant bacteria.


    Countries initiate anti-dumping probe to determine if the domestic industry has been hurt by flooding of below-cost import. As a counter-measure, they come up with duties under the multi-lateral WTO regime.


    Anti-dumping steps are taken to ensure fair trade and provide a level-playing field to the domestic industry. They are not a measure to restrict import or cause an unjustified increase in cost of products.

    amoxycillinanti-biotic medicineAurobindoDGADDirectorate General of Anti-Dumping and Allied Duties
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok